Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004981
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2000-03-13
Brief Title:
Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill Trizivir
Sponsor:
Glaxo Wellcome
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase IIIB Randomized Multicenter Study of the Efficacy and Safety of Combivir 1 Tablet Po Bid Plus Ziagen 300mg Po Bid Versus an Abacavir 300mgLamivudine 150mgZidovudine 300mg Combination Tablet Po Bid Administered for 24 Weeks in Subjects With HIV-1 Infection
Status:
UNKNOWN
Status Verified Date:
2001-06
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs zidovudine lamivudine and abacavir Zidovudine and lamivudine are often given combined in one pill Combivir In this study Trizivir will be compared to Combivir plus abacavir
Detailed Description:
Patients are randomized to receive either the triple combination tablet Trizivir or to receive Combivir plus abacavir as a separate tablet Patients take their study medications for 24 weeks
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ESS40005 | None | None | None |